SARS-CoV-2-specific hotspots in virus–host interaction networks

Schiller, Herbert B.; Breugel, Merlijn van; Nawijn, Martijn C.

doi:10.1038/s41590-021-00963-9

Cited by 5 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Large data platforms have been generated that cover the entire range of possible anti-viral drug targets for SARS-CoV-2 [18] , [49] , [50] and a detailed molecular landscape of the virus-host interaction has been established [5] , [49] , [51] , [52] . Most drug repurposing approaches targeted molecules relevant for viral replication, such as RNA-dependent RNA polymerase.…”

Section: Discussionmentioning

confidence: 99%

Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing

Luedemann

Stadler²,

Cheng³

et al. 2022

Computational and Structural Biotechnology Journal

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing

Luedemann

Stadler²,

Cheng³

et al. 2022

Computational and Structural Biotechnology Journal

View full text Add to dashboard Cite

show abstract

“…SARS-CoV-2 modulates and inhibits the host ubiquitin and ISG15 response through the expression of PLpro, which cleaves both, ubiquitin and ISG15 from proteins, disrupting antiviral functions. In addition, a number of host factors inside the ubiquitin system machinery interact with SARS-CoV-2 proteins [ 82 , 135 ] and several viral proteins are ubiquitylated [ 136 ]. Thus, it appears that SARS-CoV-2 attempts to take control of the host ubiquitin and ISG15 systems.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Targeting the Ubiquitylation and ISGylation Machinery for the Treatment of COVID-19

et al. 2022

View full text Add to dashboard Cite

Ubiquitylation and ISGylation are protein post-translational modifications (PTMs) and two of the main events involved in the activation of pattern recognition receptor (PRRs) signals allowing the host defense response to viruses. As with similar viruses, SARS-CoV-2, the virus causing COVID-19, hijacks these pathways by removing ubiquitin and/or ISG15 from proteins using a protease called PLpro, but also by interacting with enzymes involved in ubiquitin/ISG15 machinery. These enable viral replication and avoidance of the host immune system. In this review, we highlight potential points of therapeutic intervention in ubiquitin/ISG15 pathways involved in key host–pathogen interactions, such as PLpro, USP18, TRIM25, CYLD, A20, and others that could be targeted for the treatment of COVID-19, and which may prove effective in combatting current and future vaccine-resistant variants of the disease.

show abstract

“…During adaptation to a new host, viruses attempt to utilize most of the cellular enginery for their efficient replication and protein translation 1 . Viral evolution within an endemic setting frequently encompasses the co‐appearance of multiple mutations, either within a single gene or different genes.…”

Section: Introductionmentioning

confidence: 99%

Emergence of a unique SARS‐CoV‐2 Delta sub‐cluster harboring a constellation of co‐appearing non‐Spike mutations

Banerjee

Mazumder

Roy

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

Accumulation of diverse mutations across the structural and nonstructural genes is leading to rapid evolution of SARS‐CoV‐2, altering its pathogenicity. We performed whole genome sequencing of 239 SARS‐CoV‐2 RNA samples collected from both adult and pediatric patients across eastern India (West Bengal), during the second pandemic wave in India (April–May 2021). In addition to several common spike mutations within the Delta variant, a unique constellation of eight co‐appearing non‐Spike mutations was identified, which revealed a high degree of positive mutual correlation. Our results also demonstrated the dynamics of SARS‐CoV‐2 variants among unvaccinated pediatric patients. 41.4% of our studied Delta strains harbored this signature set of eight co‐appearing non‐Spike mutations and phylogenetically out‐clustered other Delta sub‐lineages like 21J, 21A, or 21I. This is the first report from eastern India that portrayed a landscape of co‐appearing mutations in the non‐Spike proteins, which might have led to the evolution of a distinct Delta subcluster. Accumulation of such mutations in SARS‐CoV‐2 may lead to the emergence of “vaccine‐evading variants.” Hence, monitoring of such non‐Spike mutations will be significant in the formulation of any future vaccines against those SARS‐CoV‐2 variants that might evade the current vaccine‐induced immunity, among both the pediatric and adult populations.

show abstract

SARS-CoV-2-specific hotspots in virus–host interaction networks

Cited by 5 publications

References 12 publications

Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing

Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing

Targeting the Ubiquitylation and ISGylation Machinery for the Treatment of COVID-19

Emergence of a unique SARS‐CoV‐2 Delta sub‐cluster harboring a constellation of co‐appearing non‐Spike mutations

Contact Info

Product

Resources

About